Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Incannex Healthcare (IXHL) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Incannex Healthcare (IXHL) over the last 2 years, with Sep 2025 value amounting to $118,173.

  • Incannex Healthcare's Gains from Investment Securities fell 49.72% to $118,173 in Q3 2025 from the same period last year, while for Sep 2025 it was $118,173, marking a year-over-year decrease of 49.72%. This contributed to the annual value of $227,508 for FY2025, which is 3.19% down from last year.
  • Latest data reveals that Incannex Healthcare reported Gains from Investment Securities of $118,173 as of Q3 2025, which was down 99.50% from $23.6 million recorded in Q2 2025.
  • In the past 5 years, Incannex Healthcare's Gains from Investment Securities registered a high of $23.6 million during Q2 2025, and its lowest value of -$1.8 million during Q1 2025.
  • Its 3-year average for Gains from Investment Securities is $3.0 million, with a median of $292,254 in 2023.
  • Examining YoY changes over the last 5 years, Incannex Healthcare's Gains from Investment Securities showed a top increase of 9,961.79% in 2025 and a maximum decrease of 621.89% in 2025.
  • Quarterly analysis of 3 years shows Incannex Healthcare's Gains from Investment Securities stood at $349,500 in 2023, then skyrocketed by 183.83% to $992,000 in 2024, then plummeted by 49.72% to $118,173 in 2025.
  • Its Gains from Investment Securities stands at $118,173 for Q3 2025, versus $23.6 million for Q2 2025 and -$1.8 million for Q1 2025.